Mr. Ohad served more than 25 years as senior executive in private and public companies. He provides significant input on NRGene’s strategic direction. He is also the chairman of OHK Medical Devices, Inc., which manufactures and sells innovative orthopedic and vascular surgery products. Mr. Ohad is the former CEO of Alqemia Group (Kafrit Industries) – a publicly traded specialty compounding firm. Former CFO of ScitexVision – (Acquired by Hewlett Packard 2005).He is an associate in the International Institute for Counter-Terrorism and received his MBA and MA from The Hebrew University of Jerusalem.
Prior to becoming CEO at NRGene, Jonathan served as CEO of MakerBot. Located in Brooklyn, New York, Jonathan was tasked with helping realign the company given significant changes taking place specifically within the Desktop 3D-Printing space, which MakerBot was leader in. Prior to that role, Jonathan was General Manager for Asia Pacific and Japan. Stationed in Hong Kong, this Distribution Unit within Stratasys accounted for roughly 25% of the group’s revenue during Jonathan’s time, with a CAGR averaging over 70% in hardware 3D-Printers during his tenure. Jonathan served as an officer (rank Lieutenant) in a Special Forces unit in the IDF.
Gil Ronen, PhDPresident & Co-Founder
Prior to establishing NRGene, Dr. Ronen was extensively involved in plant genomics at Compugen (Nasdaq: CGEN) and the AgBio discovery company Evogene (Nyse: EVGN). His last held positions at Evogene were as Chief Scientist and VP of Intellectual Property. Dr. Ronen holds a B.Sc. in Agronomy and a Ph.D. in Plant Genetics, both from The Hebrew University of Jerusalem.
Guy KolVP Strategic Accounts & Product
Mr. Kol has 15 years of experience in industrial computational biology. From 2005 to 2007, he served as the Bioinformatics team leader of Evogene, where he collaborated with Dr. Ronen. Mr. Kol holds a B.Sc. in Computer Science, Biology and Mathematics from The Hebrew University of Jerusalem, a M.Sc. in Human Genetics from Tel Aviv University and an MBA from Babson College in Wellesley, MA.
Omer Barad, PhDCTO & VP R&D
Dr. Barad has extensive experience in developing mathematical models and algorithms for the analysis of biological data. Dr. Barad joined NRGene in 2011, he lead the algorithmic team and served as the company CTO before assuming his latest role. From 2004 to 2007, he served as a senior scientist at Rosetta Genomics. Dr. Barad holds a B.Sc. in Physics and Computer Science from Tel-Aviv University, an MSc in Physics and a PhD in Life Science both from The Weizmann Institute.
Ehud BelderChief Financial Officer
Mr. Belder brings more than 10 years of experience in finance positions, with an extensive due diligence, M&A and IPO background, Mr Belder oversees finance, HR and legal activities. He held a similar role at Telsofia Medical. He also worked as senior manager of the technology sector at PwC Israel and Israel’s Ministry of Finance. He received his BA from The Hebrew University of Jerusalem and his MBA in finance from the Tel Aviv University.
Kobi Baruch, PhDVP GAS (Genomic Analysis Services)
Dr. Baruch joined NRGene in 2011 and served in a number of key roles in its R&D team before assuming his latest role. He has extensive experience in computational and molecular biology and holds a B.Sc. in computer science and biology from Bar Ilan University, an M.Sc. in genomics and bioinformatics and a Ph.D. in molecular genetics and microbiology from the Hebrew University, as well as an MBA from the Ono Academic College.